Meda licenses imiquimod for actinic keratosis from Graceway
This article was originally published in Scrip
Executive Summary
Swedish speciality pharma group Meda has bought from Graceway Pharmaceuticals the European rights to a new version of the topical immunomodulator imiquimod, which it currently markets for actinic keratosis at a higher strength under the trade name Aldara.